Nivagen Pharmaceuticals engages in the development, acquisition, and sales of generic prescription drugs and over the counter products.
Nivagen Pharmaceuticals has raised $5.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in August 2023.
Nivagen Pharmaceuticals's investors include Telegraph Hill Partners.
Nivagen Pharmaceuticals is headquartered in Sacramento, United States.
Nivagen Pharmaceuticals engages in the development, acquisition, and sales of generic prescription drugs and over the counter products.
Nivagen Pharmaceuticals is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nivagen Pharmaceuticals — Funding & Investors." VCBacked, August 9, 2023, https://www.vcbacked.co/company/nivagen-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2023). Nivagen Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nivagen-pharmaceuticals
{{cite web |title=Nivagen Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/nivagen-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated